PXN-AS1: A Potential Drug Target and Biomarker (G100506649)

Target Name: PXN-AS1

NCBI ID: G100506649

PXN-AS1

Other Name(s): EyeLinc4 | PXN antisense RNA 1

PXN-AS1: A Potential Drug Target and Biomarker

Purpose

PXN-AS1 is a protein that is expressed in the placenta and has been shown to play a role in the development and progression of various diseases, including cancer. The identification of potential drug targets and biomarkers for these diseases has the potential to improve treatment outcomes and patient outcomes.

History of PXN-AS1

PXN-AS1 was first identified in the late 1990s as a putative gene that was expressed in the placenta of various organisms, including humans. The gene was later cloned and the sequence was analyzed to determine its function. Studies have shown that PXN-AS1 is involved in the development and progression of various diseases, including cancer.

Potential Drug Targets

PXN-AS1 has been shown to interact with various proteins and has the potential to be a drug target for various diseases. One of the primary targets for PXN-AS1 is the protein tyrosine phosphatase (PTP), which is a enzyme that regulates the tyrosine phosphorylation of various intracellular proteins. PXN-AS1 has been shown to interact with PTP and prevent its tyrosination, which has the potential to inhibit the signaling pathways that are associated with the development and progression of cancer.

Another potential drug target for PXN-AS1 is the protein serine/threonine kinase (STK), which is involved in the regulation of various cellular processes, including cell growth, differentiation, and survival. PXN-AS1 has been shown to interact with STK and promote its activation, which has the potential to contribute to the development and progression of cancer.

Potential Biomarkers

PXN-AS1 has also been shown to serve as a potential biomarker for various diseases, including cancer. The levels of PXN-AS1 have been shown to be elevated in various tissues and fluids, including the placenta, which has been shown to be a site of cancer development and progression. This suggests that PXN-AS1 may be a useful biomarker for the detection and diagnosis of cancer.

Another potential biomarker for PXN-AS1 is its expression level, which has been shown to be elevated in various tissues and fluids, including the placenta, brain, and testes. This suggests that PXN-AS1 may be a useful biomarker for the detection and diagnosis of certain diseases, such as cancer.

Conclusion

PXN-AS1 is a protein that has been shown to play a role in the development and progression of various diseases, including cancer. The identification of potential drug targets and biomarkers for these diseases has the potential to improve treatment outcomes and patient outcomes. Further research is needed to fully understand the role of PXN-AS1 in the development and progression of disease and to determine its potential as a drug target and biomarker.

Protein Name: PXN Antisense RNA 1

The "PXN-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PXN-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets